Mutations in BRCA2 — a gene known to repair damaged DNA and suppress tumor formation — can predict an individuals' predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...

Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...

Poly(ADP-ribose) polymerase (PARP) inhibitors should be considered a treatment option for patients with uterine leiomyosarcomas harboring BRCA2 deep deletions, researchers advised. PARP inhibitors are ...

Hope is on the horizon for patients with aggressive, inherited breast cancers. A recent clinical trial, led by researchers at Cambridge University, explored the effects of combining chemotherapy with ...

Please provide your email address to receive an email when new articles are posted on . Researchers assigned clinical classifications to thousands of BRCA2 variants of uncertain significance. Research ...

Germline BRCA mutations have an adverse impact on both progression-free and overall survival in patients with hormone receptor-positive/HER2-negative metastatic ...

Olaparib plus abiraterone and prednisone or prednisolone already is approved in the European Union and several other countries. The FDA today approved olaparib (Lynparza) when used in combination with ...

New Study Supports Prostate Cancer Active Surveillance Compared with noncarriers, BRCA carriers experience metastatic prostate cancer sooner and have shorter survival. Following radical treatment for ...

Researchers found that losing a second protein, FIGNL1, allows cancer cells missing BRCA2 to restore DNA repair by reloading RAD51 onto broken DNA strands. Normally, BRCA2 helps place RAD51 at DNA ...

“Breast cancer was the furthest thing from my mind,” Jacob Johnson tells PEOPLE ...